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Abstract
Background: The ETS transcription factor Elf5 (also known as ESE-2) is highly expressed in the mammary gland
and plays an important role in its development and differentiation. Indeed studies in mice have illustrated an
essential role for Elf5 in directing alveologenesis during pregnancy. Although the molecular mechanisms that
underlie the developmental block in Elf5 null mammary glands are beginning to be unraveled, this investigation
has been hampered by limited information about the identity of Elf5-target genes. To address this shortcoming, in
this study we have performed ChIP-cloning experiments to identify the specific genomic segments that are
occupied by Elf5 in pregnant mouse mammary glands.
Results: Sequencing and genomic localization of cis-regulatory regions bound by Elf5 in vivo has identified several
potential target genes covering broad functional categories. A subset of these target genes demonstrates higher
expression levels in Elf5-null mammary glands suggesting a repressive functional role for this transcription factor.
Here we focus on one putative target of Elf5, the Ccnd2 gene that appeared in our screen. We identify a novel
Elf5-binding segment upstream of the Ccnd2 gene and demonstrate that Elf5 can transcriptionally repress Ccnd2
by directly binding to the proximal promoter region. Finally, using Elf5-null mammary epithelial cells and mammary
glands, we show that loss of Elf5 in vivo leads to up regulation of Ccnd2 and an altered expression pattern in
luminal cells.
Conclusions: Identification of Elf5-targets is an essential first step in elucidating the transcriptional landscape that
is shaped by this important regulator. Our studies offer new toolbox in examining the biological role of Elf5 in
mammary gland development and differentiation.
Background
Ets transcription factors are highly conserved proteins that
have a unique 85 amino acid DNA-binding domain. Ets
proteins activate or repress the expression of a myriad of
genes that are involved in various biological processes,
including cellular proliferation, apoptosis, differentiation,
and transformation [1]. Typically, Ets proteins directly
bind to regulatory elements such as promoters and enhan-
cers that contain a GGAA/T core sequence motif thereby
regulating target gene expression. This protein family con-
sists of 25-30 members in mammals, which are broadly
expressed in a variety of tissues and their relative expres-
sion differs according to cell type. This poses a challenging
task of determining which of these Ets proteins are biolo-
gically active in a given cellular environment and to link a
specific Ets protein to its target.
The mammary epithelium and cell lines derived from
mammary tissues and tumors express a number of Ets
factors [2-4]. The critical function of some of these Ets
factors in mammary gland development, differentiation
and tumorigenesis is dramatically reflected in the phe-
notypes observed in transgenic and knockout mouse
studies [3]. One such Ets factor is Elf5 (also called ESE-
2), which is highly restricted to tissues and organs rich
in glandular or secretory epithelial cells including the
mammary luminal epithelium [5,6]. The first hint as to
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development came from studies showing that Elf5 het-
erozygous female mice display impaired mammary
alveolar morphogenesis [7]. However, the fact that Elf5-
null mice die very early during embryogenesis due to
developmental defects in the formation of extraembryo-
nic ectoderm limited further studies [8]. To overcome
this, we and others have investigated the effects of the
complete loss of Elf5 using tissue-specific knockout
models and mammary transplants [9,10]. Mammary
glands that are deficient in Elf5 completely fail to initi-
ate alveologenesis during pregnancy and retain charac-
teristics of virgin ductal epithelial cells. Furthermore,
Elf5-null mammary glands accumulate CD61+ luminal
progenitor cells supporting a critical role for Elf5 in spe-
cifying the differentiation of mammary epithelial pro-
genitors to establish secretory alveolar lineage [9]. Our
studies have also shown that Elf5 transcriptionally regu-
lates the expression of key mediators of the Prolactin/
Jak2/Stat5 signaling pathway, and alterations in this
pathway might be partly responsible for the Elf5-null
mammary gland phenotype [10]. These studies have
unearthed a wealth of information about the biological
role of Elf5 in mammary gland development and estab-
lished Elf5 as a critical transcription factor that dictates
cell fate and lineage choices.
While the importance of Elf5 in normal mammary
gland development is firmly established, whether it acts
as a tumor suppressor or an oncogene in breast tumori-
genesis remains to be determined. Interestingly, ELF5 is
localized to human chromosome 11p13-15, a region of
the genome, which undergoes loss of heterozygosity
(LOH) in many types of cancer, including ductal carci-
noma of the breast [5]. Preliminary studies have demon-
strated that loss of Elf5 is frequently found in human
mammary carcinoma cells and Elf5 mRNA expression
also is lost in a number of breast cancers compared to
adjacent normal tissues [5,11]. These observations are in
agreement with a recent study on MMTV-Wnt-1 mur-
ine breast tumors, which showed that Elf5 expression
was significantly diminished in the tumorigenic com-
partment [12]. However these results are in contrast to
expression analysis studies of breast cancer by other
laboratories, which have suggested increased Elf5
expression in breast cancer [2,4]. Notwithstanding the
lack of a clear-cut role of Elf5 in tumor development, it
is safe to posit that this transcription factor is an impor-
tant mediator of various facets of mammary gland biol-
ogy and warrants further experimental studies.
Identification of the repertoire of its target genes is one
such critical step in better understanding the molecular
mechanisms underlying Elf5 function.
Our biochemical studies have demonstrated that the
Ets domain of Elf5 acts as a transcriptional repressor,
whereas the N-terminal Pointed domain can function as
a transcriptional activator [13]. These observations fit
well with studies on some putative Elf5-target promoters
such as PSA, SPRR2A, Keratin 8, and WAP promoters,
which have shown that Elf5 can activate or repress tran-
scription in a context-dependent manner [9,10,14].
However, a global analysis of Elf5-binding events is lack-
ing, and our current knowledge of what are bona-fide
Elf5-targets is extrapolated from a limited number of
examples that have been obtained from in vitro binding
studies and reporter assays in keratinocytes. To over-
come this shortcoming, here we have applied a chroma-
tin immunoprecipitation (ChIP)-cloning strategy with
validated ChIP-grade anti-Elf5 antibodies to identify
genetic loci bound by Elf5 in mammary epithelium. Our
studies have identified numerous physiologically relevant
downstream targets of Elf5 including several of known
significance in the development and function of mam-
mary glands. As a proof of principle to demonstrate the
validity of our approach and to further elucidate the
role of Elf5 in mammary glands, we have focused our
studies on Ccnd2 (cyclin D2). We show that Elf5 binds
to a conserved site within an upstream regulatory ele-
ment as well as the proximal promoter of the Ccnd2
gene and that the expression level of cyclin D2 is upre-
gulated by the loss of Elf5 in mammary epithelial cells
in culture as well as in Elf5 deficient mammary glands.
Collectively our ChIP approach has identified numerous
mouse target genes of Elf5 and has offered insight into
the regulatory pathways controlled by Elf5 during mam-
mary gland morphogenesis and cancer.
Results and Discussion
Assessing the efficacy of Elf5-antibodies for chromatin
immunoprecipitation
Although the commonly used commercial Elf5 antibody
(N-20) shows robust activity in detecting the endogen-
ous protein by both western blot and immunostaining
and has been used sporadically for ChIP experiments, its
efficiency in immunoprecipitating endogenous Elf5 has
not been experimentally determined. Hence, we took
advantage of a recently described Gal4-based cell culture
system to test the efficacy of anti-Elf5 antibodies [15].
HEK293 UAS-TK-Luc is a human cell line with a Gal4-
responsive luciferase gene integrated into the genome.
Our goal was to test if the N-20 antibodies are capable
of recognizing its specific epitopes under harsh condi-
tions, those typically associated with ChIP experiments
such as formaldehyde crosslinking and stringent wash-
ing. This also allowed us to assess how well the N-20
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dies against another DNA-binding protein such as Gal4.
For this purpose, we transfected the HEK293 UAS-TK-
Luc cell line with plasmids expressing either the Gal4
DNA binding domain or a chimeric protein consisting
of Gal4 DNA binding fused to Elf5 and confirmed the
expression of the proteins by western blot analysis with
anti-Gal4 and anti-Elf5 antibodies (Fig 1A and 1B). The
transfected cells were then subjected to ChIP using anti-
bodies against Gal4 and Elf5. When PCR was performed
with ChIPed DNA for the Gal4-responsive UAS region,
as expected, a significant enrichment was observed
specifically with anti-Gal4 antibodies in cells transfected
with plasmids encoding Gal4 DNA binding (Fig 1C). On
the other hand, in cells transfected with Gal4 DBD-Elf5,
enrichment was obtained when using both the Gal4 and
Elf5 antibodies. This enrichment was specific, since con-
trol lanes (no antibodies or IgG) did not show any PCR
products and only background levels of products were
obtained in untransfected cells. Interestingly, under
these conditions, the Elf5 antibodies performed as well
as, if not better than the Gal4 antibodies, confirming its
usefulness for ChIP experiments to detect genomic tar-
gets. One potential caveat however is the fact that this
experiment was performed on Gal4-Elf5 fusion protein,
and the presence of Gal4 DNA binding domain might
influence the overall conformation and accessibility of
the epitope. Thus it is conceivable that the N-20 antibo-
dies may be more (or less) competent and specific in
immunoprecipitating endogenous Elf5.
Chromatin immunoprecipitation of mammary epithelium
with anti-Elf5 antibodies and cloning of Elf5-bound
genomic segments
Having established that the N-20 anti-Elf5 antibodies are
well suited for ChIP experiments, we next decided to
identify the in vivo target genes of Elf5 in mouse mam-
mary glands obtained from 17.5 days of pregnancy.
Importantly, Elf5 is highly expressed during this stage of
alveolar maturation and knockout studies have clearly
demonstrated an indispensable role for this transcription
factor in alveologenesis. Using the N-20 antibodies, we
prepared a library of chromatin-DNA immunoprecipi-
tated from mammary glands. To overcome the technical
challenge associated with limiting amounts of DNA
obtained during the ChIP procedure, we utilized a liga-
tion-mediated PCR technique, a method successfully
used by our laboratory in prior studies (Fig 1D) [16]. In
addition, to reduce non-specific DNA contamination, we
purified the PCR-amplified fragments by incubation with
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Figure 1 Assessment of anti-Elf5 antibody for ChIP. The Elf5 antibody was tested for ChIP using the human cell line HEK293 UAS-TK-Luc,
which contains a stably integrated luciferase reporter gene under the control of UAS (containing Gal4 binding sites) and the TK promoter. A.
Schematic representation of the plasmids and primers utilized in the experiment. B. Expression of the Gal4 proteins assessed by anti-Gal4 and anti-Elf5
antibodies. HEK293 UAS-TK-Luc cells were transfected with plasmids that express Gal4 DNA-binding domain (Gal4 DBD) or Gal4 DBD-Elf5. C. ChIP
assays performed with anti-Gal4 DBD or with anti-Elf5 antibodies. Immunoprecipitated DNA was analyzed using P1 and P2 primers. As a positive
control, an aliquot (1%) of chromatin complex before immune isolation was used as input for PCR. Nonspecific binding was judged using rabbit
IgG or no antibody. D. Schematic overview of the ChIP protocol used for the cloning of Elf5-putative target genes.
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Page 3 of 16agarose beads containing GST-Elf5 protein. This enrich-
ment procedure allowed us to select for DNA fragments
that are more likely to contain DNA binding-sites for
Elf5. Using this strategy, we isolated and sequenced 202
clones. Of the 202 sequenced clones, we found that
there were 18 duplicate sequences, and 1 could not be
mapped to a specific location in the mouse genome.
This resulted in a final 183 unique mouse clones, which
were analyzed by mapping them to the mouse genome
database by using a variety of search programs including
the University of California Santa Cruz genome browser,
ENSEMBL, or the BLAST program at NCBI. This
allowed us to determine the location of the Elf5-immu-
noprecipitated DNA fragments in relation to known or
predicted genes.
Our study revealed that 154 DNA fragments out of
the 183 unique clones immunoprecipitated by anti-Elf5
antibodies were embedded within or located near
known, annotated, or predicted genes. We chose to
assign the DNA fragments to a specific gene if the
sequence matched to the intragenic region or a segment
within 100 kb upstream or downstream. The 154 gene-
associated Elf5-binding fragments identified by this
approach are listed in Table 1 (see Additional File 1)
with their genomic coordinates. The remaining 29 frag-
ments that did not map to genomic regions close to any
gene may represent distal enhancers involved in regulat-
ing gene expression from distances significantly farther
than 100 kb, a characteristic found in some enhancers.
Alternatively, these segments may denote non-annotated
regions of the genome that do not encode for conven-
tional genes but are sites for miRNA and similar ele-
ments. Some of these elements may also represent
experimental artifacts resulting from non-specific DNA-
binding of Elf5 to certain chromatin regions that are
captured during formaldehyde cross-linking or contami-
nating DNA obtained during the immunoprecipitation
or PCR enrichment steps.
Characteristic Features of the Elf5 target regions
Examination of the 154 Elf5 occupied target fragments
revealed several interesting findings. Forty five percent
of the Elf5-ChIP fragments were located within an
intron of known or predicted genes, with a large propor-
tion of them in the first intron (Fig 2A). A majority of
the DNA fragments chromatin immunoprecipitated by
Elf5 was located within a region spanning 100-kb
upstream or downstream of candidate target genes. This
observation is in agreement with many other transcrip-
tion factors such as Gata-1, Foxa2, TCF4 for which
genomic binding sites have been deciphered on a large
scale and reflects the growing evidence for the presence
of intragenic and distant extragenic cis-regulatory
regions for transcriptional control [17-20]. Although
several sites were located less than 10-kb upstream of a
transcription start site (8%), only a small number
mapped to the promoter proximal regions. This may
reflect the propensity of Elf5 to act primarily through
distal enhancers or simply signify under-representation
of promoter regions since they are not well defined and
properly annotated for many mouse genes.
Interestingly, some Elf5-ChIPed DNA fragments were
located in between two genes. In these cases, although
we have only chosen the nearest located gene as a
potential Elf5-regulatable gene for subsequent analysis,
it is possible the distally located gene may be the actual
Elf5-target. For example, one of the immunoprecipitated
DNA fragments mapped to a region that is upstream of
the Elf5 gene itself suggesting this region could function
as an enhancer for Elf5. This is of particular interest
given the propensity of many transcription factors to
auto-regulate themselves through DNA-binding ele-
ments located in their regulatory regions. However, the
Elf5 gene lies close to a family member Ehf (also called
ESE-3) in a head-to-tail orientation. Due to this close
proximity, the Elf5-ChIPed fragment maps to a region
~50 kb away from Elf5 and ~66 Kb from Ehf. In view of
the overlapping expression pattern and similar biological
role of Elf5 and Ehf in epithelial development, it is quite
possible that the Elf5-response element located in the
intergenic region may coordinately regulate the expres-
sion of both these genes.
Elf5-target sites are broadly located on all mouse chro-
mosomes, suggesting a broad and unbiased distribution
across the mouse genome (Fig 2B). Functional classifica-
tion of these potential targets based on Gene Ontology
categorization revealed that these are widely distributed
among a wide variety of categories including transcrip-
tional regulation, signaling cascades and metabolism (Fig
2C). The diverse nature of the targets identified in our
study reinforces the notion that Elf5 plays a role in com-
plex biological pathways that affect a wide variety of cel-
lular processes. Given the proposed role of Elf5 in
regulating the gene expression of milk proteins during
alveologenesis, we were surprised that no such gene was
found in our ChIP data. Since by some estimates, tran-
scription factors are thought to bind to ~thousands of
genomic sites, the absence of any milk protein genes in
our Elf5 target list could be due to the small sample size.
We next searched ChIP-identified sequences of the
154 identified targets to find DNA-binding motifs that
may be indicative of Elf5 binding sites. Previous studies
have attempted to define the consensus Elf5 DNA bind-
ing site based on gelshift binding assays and in vitro
selection experiments. Although these studies have
revealed slightly different consensus sites for Elf5 such
as 5′-(A/C)GGAA(A/G)(G/T)(A/G)NNC-3′ [14] and 5′-
ANCAGGAAGTAN-3′ [6] and 5′-(A/C)GGAA(A/G)(G/
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Page 4 of 16T)(A/G)NNC-3′ [13] - they all contain the invariant
GGAA core sequence, but differing flanking sequence.
Hence, we searched the 154 Elf5-ChIPed segments in a
biased manner using the GGAA position weight matrix
(PWM) as a query for the pattern-recognition program
Patser. This analysis showed that the GGAA core motif
is highly enriched within ChIP-identified Elf5 target
regions. Indeed, at least one GGAA motif was identified
in all ChIP-cloned fragments, whereas several DNA seg-
ments with multiple GGAA elements were identified by
t h eP a t s e rp r o g r a mw i t he - v a l u ec u t o f f- 5 .T h e s en u m -
bers were lower when a more stringent e-value cut off
of -6 was used, however the trend remained the same.
The consensus DNA-binding site for Elf5 based on the
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Page 5 of 16ChIPed genomic sequence is quite similar to that pre-
viously described as shown in the weblogo generated
from our current data (Fig 2D). The fact that many of
the potential Elf5-binding sites identified by ChIP were
highly conserved support the notion that these sites are
likely to be functionally relevant (data not shown).
Confirmation of a subset of Elf5 target genes by
independent ChIP assays and their expression levels in
the absence of Elf5
To facilitate further studies of the potential Elf5 targets,
we selected thirteen genomic loci identified by ChIP.
These DNA fragments immunoprecipitated by Elf5 were
chosen to represent the wide range of distinct character-
istics such as potential function of the target genes, dif-
ferent locations relative to the target genes (5′,3 ′ or
intragenic), and whether the Elf5-binding segments were
close to one or more target genes (Additional File 2, Fig
S1). However given the importance of Elf5 to mammary
gland development and differentiation, we focused on a
few genes that were transcription factors (such as
Trp63, ESR1, Ets2) or key members of signaling path-
ways (such as Notch1 and Wnt11)t h a ta r er e l e v a n tt o
mammary gland biology. For these experiments, cross-
linked chromatin from mouse mammary glands was
immunoprecipitated in two independent experiments
with anti-Elf5 antibodies and the co-precipitation of the
Elf5-response elements was ascertained by PCR with
primers that amplify the chosen thirteen fragments. As
a negative control we utilized a genomic segment corre-
sponding to a segment of the Gapdh gene. As shown in
Fig 3, after immunoprecipitation of cross-linked chro-
matin we found that there was specific enrichment of all
potential Elf5-response elements, but not Gapdh with
antibodies against Elf5 compared to IgG or no antibody
control. Although for most of the genomic fragments,
the extent of specific amplification that was observed
was robust, in a few cases the PCR product was only
marginally stronger than the control suggesting that
there is a great deal of variability in the extent of
recruitment of Elf5 to these sites. This might reflect the
strength and number of Elf5-binding sites, presence of
additional transcription factor binding to these regions
and/or specific regulatory events that are dictated by the
differentiation state of the mammary epithelial cells.
Next we performed real time RT-PCR experiments to
test if genes associated with the thirteen genomic loci
were indeed expressed in mammary glands and if their
expression levels were altered in the absence of Elf5. We
have previously shown that mammary epithelium-speci-
fic conditional deletion of Elf5 leads to a complete block
in alveologenesis during lactation. Given the strong
expression of Elf5 in mammary glands at 17.5 day of
pregnancy and the dramatic phenotype observed in
lactating day 1, these two time frames were chosen for
further studies. We isolated RNA from mammary glands
from K14-Cre/Elf5
f/f animals and their WT littermate
controls (K14-Cre/Elf5
+/+). The real time PCR data
revealed that majority of the genes showed significant
differences in their level of expression in Elf5-null mam-
mary glands compared to wild type controls (Fig 3B).
Interestingly, of the several candidate genes chosen, two
of them, Dlx1 and Tbx4 showed no detectable expres-
sion in mammary glands under our experimental condi-
tions. It is possible that the Elf5-ChIPed fragment
located close to the Dlx1 gene might alternatively be
involved in regulating the Metapl1 gene, situated on the
3′ end (Fig S1). On the other hand, the complete lack of
expression of Tbx4 in mammary gland is more puzzling
and raises the possibility that the corresponding geno-
mic fragment obtained in our screen is perhaps non-
functional, representing either fortuitous binding or an
experimental artifact. One interesting aspect of these
studies is that majority of the genes that were examined
showed up regulation in the absence of Elf5. This sug-
gests that Elf5 may act broadly as a transcriptional
r e p r e s s o r ,ap r o p e r t yt h a tw eh a do b s e r v e di no u rp r e -
vious biochemical experiments [13]. Another aspect that
caught our attention is that many of the potential Elf5
target genes are myoepithelial/basal restricted (Trp63
for example). This might reflect a propensity for Elf5 to
suppress myoepithelial gene expression and foster a
luminal cell fate.
Identification of Ccnd2 as a direct Elf5 target
Having shown that our strategy for finding Elf5-targets
was successful, we decided to focus on one putative tar-
get gene Ccnd2 (cyclin D2) for further detailed examina-
tion. This was prompted by several observations
including a prior study that demonstrated that trans-
genic mice expressing high levels of cyclin D2 under the
MMTV promoter exhibit a lack of alveologenesis and a
failure to lactate - a phenotype that mimics that of the
Elf5 knockouts [21]. Furthermore, the Elf5 ChIPed frag-
ment corresponded to an evolutionarily conserved DNA
segment ~60 Kb upstream of the mouse Ccnd2 gene
suggesting that this region was likely to play a functional
role (see Additional File 3, Fig S2 and Fig 4A). The
upstream segment contained two potential Elf5-binding
sites. We reasoned that if Elf5 directly regulated the
expression of Ccnd2, it was likely to also interact with
the promoter region. A careful examination of the prox-
imal promoter sequence revealed a consensus Elf5-bind-
ing site at -65 to -60 upstream of the transcriptional
start site (Additional File 4, Fig S3).
We therefore probed if these potential Elf5-binding sites
were directly capable of interacting with Elf5. For this
purpose, full-length Elf5 protein was expressed in E. coli
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Figure 3 Verification of putative Elf5 target DNA by independent ChIP and examination of their expression levels in Elf5 null-mouse
mammary glands. A. Independent ChIP assay to demonstrate Elf5 occupancy. Mouse mammary gland at pregnancy day 17.5 were
immunoprecipitated with anti-Elf5 antibodies and analyzed by PCR using specific primers that amplified genomic DNA segments located close
to putative Elf5 target genes and Gapdh as negative control. As positive control of PCR, an aliquot (1%) of chromatin complex before immune
isolation was used as input. Nonspecific binding was assessed using goat IgG or no antibody. B. Realtime RT-PCR analysis of Elf5 target genes in
WT and Elf5-null mammary gland. Total RNA from wild type (WT) and K14-Cre/Elf5
f/f (Elf5 null) mouse mammary glands at pregnancy day 17.5
and lactation day 1 were analyzed for relative expression of mRNA levels of putative Elf5 target genes by real time RT-PCR. Data shown is from
at least two independent experiments.
Escamilla-Hernandez et al. BMC Molecular Biology 2010, 11:68
http://www.biomedcentral.com/1471-2199/11/68
Page 7 of 16as a GST-fusion protein. In addition, we also generated
Elf5 GST-fusion proteins containing specific mutations
in amino acids R219 and K216 located in the DNA-
binding domain. We reasoned that based on sequence
conservation of the Ets domain, these two amino acids
are likely to be critical mediators of Elf5-DNA binding.
For example, in case of the ETS transcription factor,
PDEF, the Ets domain makes a number of contacts with
its DNA substrate [22]. One site of major interaction
with bases occur at the conserved arginine residue
R307, which make key hydrogen bonds with the GGA
c o r e ,w h e r e a sah i g h l yc o n s e r v e dl y s i n e ,K 3 0 4 ,i s
thought to be involved in the tethering of DNA along
with other residues to properly orient the DNA mole-
cule. These two residues of PDEF are the counterparts
of R219 and K216 in Elf5 and hence likely to be impor-
tant for DNA-binding. The wildtype and mutant GST-
Elf5 proteins were purified to reasonable homogeneity
(Additional File 5, Fig S4) and tested for their ability to
bind to oligonucleotides containing Elf5 consensus
DNA-binding sequences by gelshift experiment. As
expected, while wildtype GST-Elf5 protein strongly
bound to DNA, the mutants completely failed (data not
shown).
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Figure 4 Binding of Elf5 to regulatory regions of the CCND2 gene. A. A schematic map of the cyclinD2 gene showing the genomic structure
and the location of the Elf5-ChIPed segment in the 5’ upstream region (circle). The primer sets used for ChIP experiments are shown. B. Gelshift
experiments to demonstrate binding of recombinant Elf5 to cyclinD2 regulatory regions. The Elf5-DNA complex is supershifted (*) with the addition
of two different antibodies against Elf5, Ab1 (N-20) and Ab2 (generated in the laboratory). Lanes 1-7 represent data with the oligonucleotide
corresponding to the cyclinD2 promoter, whereas lanes 8-12 and 13-17 correspond to two segments of the upstream region that contain Elf5-
binding sites. C. In vivo occupancy of Elf5 on mouse Ccnd2 gene. ChIP was performed on mouse mammary glands using antibodies recognizing
Elf5 as well as a nonspecific IgG as indicated. Input represents PCR amplification of 1% of the genomic DNA. Primer pairs P1-P2 and P3-4
correspond to the upstream and the promoter region respectively. P5-P6 corresponds to 3’ region of Ccnd2 gene and serves as a negative
control. Results shown are a representative of two independent experiments. D. The cyclin D2 promoter is repressed by Elf5 in reporter gene assays
in mammary epithelial cells. The wildtype (black) or mutant (white) cyclinD2-Luc plasmid was co-transfected with expression plasmids encoding
Elf5 or Elf3 into MCF-7 cells. Luciferase values were determined and normalized against b-galactosidase values. The corrected luciferase values for
cells transfected with empty vector pCMV-HA were set at 1.
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sponding to the three Elf5-consensus sequences. These
probes were labeled to approximately the same level of
specific activity and tested by gelshift assays with GST-
Elf5 and GST Elf5 mutant proteins. As shown in Fig.
4B, GST-Elf5 showed strong binding to the promoter
sequences of cyclin D2 whereas both mutants did not
show any detectable binding. The DNA-protein complex
could be supershifted with two different antibodies
against Elf5 confirming the specificity of the complex
(left panel). In a similar fashion, oligonucleotides con-
taining two distinct Elf5-consensus sites embedded
within the cyclin D2 upstream element were also cap-
able of forming complexes specifically with GST-Elf5
but not with either of the mutants (middle and right
panel). Interestingly, the DNA-protein complex with
both the oligonucleotides of the upstream element was
relatively weaker as compared to the promoter region.
This suggested that the promoter sequence likely corre-
sponded to a high-affinity Elf5-binding site and reaf-
firmed the notion that sequences flanking the core
GGAA motif significantly influence binding activity as
demonstrated before.
To clearly demonstrate that Ccnd2 is a direct target
gene of Elf5 we performed an independent ChIP assay
(Fig. 4C). We used anti-Elf5 antibodies to immunopreci-
pitate crosslinked chromatin from mouse mammary tis-
sue. We designed a set of primers (P1 and P2) to
amplify the putative cyclinD2 upstream element identi-
fied in our screen and the proximal promoter region
(P3-P4). As a control, we designed a set of primers (P5-
P6) that amplify a random region of genomic segment
3′ of the Ccnd2 gene that did not show any sequence
conservation. As shown by PCR data in Fig. 4C, specific
enrichment of the cyclin D2 5′ upstream and promoter
region, but not the 3′ downstream element was observed
after immunoprecipitation with antibodies against Elf5
as compared to the IgG or no antibody control. This
suggested that in vivo Elf5 physically occupies the regu-
latory elements of the Ccnd2 gene and given the pre-
sence of Elf5-binding sites, we posit that this is a direct
interaction.
Having demonstrated that Elf5 can directly bind to the
cis elements of the Ccnd2 gene, our next goal was to
determine if the expression of this gene was transcrip-
tionally responsive to Elf5. For this purpose we focused
on the cyclinD2 proximal promoter region, given the
presence of a strong Elf5-binding site in this segment.
The mouse cyclinD2 promoter was cloned into pGL3-
basic vector and assayed for reporter activity. As a con-
trol, we generated a mutant pGL3-Ccnd2 promoter
where the core GGA element of the Elf5-binding site
was mutated. We utilized MCF-7 cells for the transient
transfection experiments since these cells have been
shown to lack endogenous Elf5 expression [5,6]. When
transfected in these cells, pGL3-Ccnd2 promoter showed
significant luciferase activity compared to the empty
pGL3 vector suggesting that the promoter was active in
these cells. Next, the reporter plasmid was cotransfected
with either an expression plasmid encoding for HA-
tagged Elf5, HA-tagged Elf3 (a closely related family
member) or an empty HA-control vector. The expres-
sion of the HA-tagged Elf5 and HA-tagged Elf3 proteins
were confirmed by western blot analysis with anti-HA
antibodies (Additional File 6, Fig S5). As demonstrated
in Fig. 4D, expression of both Elf3 and Elf5 resulted in
decreased levels of reporter activity, although the effects
of Elf5 were clearly more pronounced (4-5 fold repres-
sion). This repressive effect of Elf5 was significantly,
although not completely, relieved when the pGL3-
Ccnd2 promoter containing the mutant Elf5-binding site
was utilized under the same conditions. This data sug-
gests that Elf5 can act as a repressor and inhibit the
activity of the proximal mouse cyclinD2 promoter.
Expression pattern of Elf5 and cyclin D2 in mouse
mammary glands
The expression pattern of cyclin D2 in mammary glands
is quite dynamic. In one study, it was reported that
cyclin D2 was not easily detectable in mammary glands
at any stages of development as measured by Western
blot analysis [21]. However, immunostaining data sug-
gested that in virgin glands, cyclinD2 protein was loca-
lized predominantly in the myoepithelial cells. On the
other hand, cyclinD2 was reported to be expressed in
both myoepithelial and luminal epithelial cells at the
RNA level in normal human breast samples [23]. Given
this discrepancy, we decided to re-examine the expres-
sion profile of cyclin D2 using data from a microarray
analysis that was performed on mammary glands
obtained at different stages of development spanning the
virgin state to involution [24]. The expression profile
shown in Fig 5A clearly demonstrate a dynamic expres-
sion of cyclin D2 with a steady level throughout the vir-
gin stages and early pregnancy but then dramatic
reduction at mid pregnancy. During the same period,
Elf5 showed an opposite pattern with low expression
levels during virgin stages and early pregnancy and a
progressive surge in expression from P12.5 onwards that
coincided with the downregulation of cyclin D2. This
reciprocal mode of expression is further suggestive of
Elf5′s role as a potential repressor keeping cyclin D2
expression in check.
If Elf5 is an important transcriptional regulator of
cyclin D2, we hypothesized that in its absence; there will
be changes in the expression of cyclin D2. To test this,
we isolated total RNA from wild type control and Elf5-
null mammary glands, generated cDNAs and performed
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Page 9 of 16real time PCR. While in P17.5 mammary glands, the
expression of cyclin D2 was modestly higher in Elf5
knockout, by lactation day 1, this difference was signifi-
cantly more pronounced (Fig 5B). To examine if these
changes in transcript also correlated with protein level,
we performed western blot analysis with mammary
gland extracts. In agreement with mRNA levels, cyclin
D2 protein was upregulated in the samples from lacta-
tion day 1 in Elf5-null mammary glands compared to
wildtype control (Fig 5C). We also examined the expres-
sion of p27
kip1, a cyclin dependent kinase inhibitor
shown to be important in activation of cyclin D-CDK4
complexes [25]. Indeed, in the MMTV-cyclin D2 over-
expressing mice, the mammary gland phenotype has
been attributed in part to increased p27
kip1 protein
levels [21]. However, the interactions between these cell
cycle regulators are likely to be complex and context
dependent. For example, cell culture based studies have
shown that overexpression of cyclin D2 affect the trans-
location of p27 from the nucleus to the cytoplasm and
promotes its degradation [26]. Western blot analysis
showed that although there was a modest reduction in
protein levels of p27
kip1 in p17.5 mammary glands in
the absence of Elf5, the expression was restored to nor-
mal levels in lactating animals. The significance of this
alteration in p27 levels is currently unknown and worth
future investigation.
Expression of Ccnd2 in the absence of Elf5
To determine the transcriptional effects of Elf5 on
Ccnd2 in a more physiological setting, we decided to
examine mammary epithelial cells (MECs) isolated from
Elf5 conditional knockout (Elf5
f/f) animals. We have pre-
viously shown [10] that in these MECs, Elf5 can be
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Figure 5 Expression analysis of cyclin D2 as a potential Elf5 target gene. A. The expression pattern of cyclin D2 and Elf5 during different
stages of mammary gland development. The expression profile was generated by analysis of microarray data from Stein et al[24]. B. Relative
expression of cyclin D2 mRNA by real time RT-PCR during mouse mammary gland development. Total RNA from wild type (WT) and K14-Cre/Elf5
f/f
(null) mouse mammary glands at pregnancy day 17.5 and lactation day 1 were analyzed for relative expression of Ccnd2 mRNA levels by real
time RT-PCR. The housekeeping gene Gapdh was used to normalize gene expression. Results are from two or more independent experiments. C.
Expression of cyclin D2 protein during mouse mammary gland development. Protein extract from wild type (WT) and K14-Cre/Elf5
f/f knockout (KO)
mouse mammary glands at pregnancy day 17.5 and lactation day 1 were analyzed by western blot with antibodies against cyclin D2 and p27.
Equal loading was assessed by anti-b-tubulin antibodies and the absence of Elf5 in KO was confirmed by anti-Elf5 antibodies.
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Page 10 of 16inactivated by expression of Cre recombinase by using
adenoviral vectors (Ad-Cre). MECs were harvested from
Elf5
f/f mice and infected with either Ad-Cre or Ad-GFP
and cultured on basement membrane matrix for varying
time points. As we have demonstrated before, infection
of MECs with adenovirus expressing Cre resulted in a
significant knockdown of Elf5 expression by 48 h after
infection with virtually no detectable protein after 72 h.
To examine cyclin D2 levels, protein lysates were har-
vested from MECs and western blots were performed.
Loss of Elf5 leads to a strong increase in Ccnd2 further
supporting the notion that Elf5 acts as a repressor of
the Ccnd2 gene (Additional File 7, Fig S6).
To further probe the effects of loss of Elf5 during
pregnancy, we compared mammary glands from K14-
Cre/Elf5
f/f animals and their wildtype type littermate
controls (K14-Cre/Elf5
+/+) by immunofluorescent stain-
ing with anti-Ccnd2 antibodies. At P12.5, in WT mam-
mary glands, Ccnd2 was predominantly restricted to the
outer myoepithelial cells, where they showed a patchy
expression pattern whereas no staining was detected in
the luminal cells. In contrast, in Elf5-null mammary
glands, Ccnd2 expression clearly extended into the lumi-
nal cells (Fig 6). The altered expression profile of Ccnd2
was also observed in the P17.5 day samples, where more
luminal cells stained positive for Ccnd2 in the collapsed
ductal structures that are present in the Elf5-null
mammary glands. These results suggest that in normal
luminal cells, Elf5 keeps cyclin D2 expression in check
and that in its absence, cyclin D2 is turned on in at
least a subset of the luminal cells. It has been shown
that in the absence of Elf5, there is decreased prolifera-
tion in the pregnant mammary glands [7,10]. Interest-
ingly it was also shown that there is an increase in
CD61+ luminal progenitors in the Elf5-null mammary
epithelium [9]. We posit that the luminal cells with
higher levels of cyclin D2 might represent a selective
population of these luminal progenitor cells, which pos-
sess a higher proliferative potential.
Conclusions
The identification of Ccnd2 as a direct target of Elf5 is a
novel finding and has implications for the proliferative
decisions of mammary epithelial cells during normal
development as well as in cancer. In this context, it is
also interesting to note that a closer examination of the
recently generated microarray analysis of sorted mam-
mary stem/progenitor cell populations reveal that in
both the human mammary stem cell (CD49
hi Epcam
low
enriched) and bipotent progenitor cell populations (Ma-
CFC enriched), CCND2 is one of the most highly
expressed transcript [27,28]. This is particularly impor-
tant since our preliminary studies suggest that loss of
Elf5 during pregnancy leads to increase in stem and
Figure 6 Altered expression of Ccnd2 and p27 during pregnancy. (A-D) P12.5 (E-H) P17.5. At P12.5, in WT tissues Ccnd2 was expressed
exclusively in the basal cells (yellow arrowhead) (A). However, in Elf5-deficient tissue (K14-Cre/Elf5
f/f) at P12.5 frequently cells were observed in
luminal compartment that were positive for Ccnd2 (yellow arrowhead=basal position, white arrowhead=luminal position in C). At later time
points during pregnancy (P17.5), Ccnd2 was expressed predominantly at the basal cells (yellow arrowhead) in the WT tissue (E). Few luminal cells
were positive for Ccnd2 (white arrowhead). In the Elf5-deficient tissues, large number of Ccnd2 positive cells was observed in the luminal
compartment (white arrowhead, G). Yellow arrowheads show localization of Ccnd2 in basal cells.
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Page 11 of 16progenitor cell population (unpublished data). Although
in this study we demonstrate Elf5 as one transcription
factor that keeps cyclin D2 repressed, this important cell
cycle regulator is likely to be controlled by additional
transcription factors. Indeed there is published data
linking Stat5, Sp1, myc and GATA4 to the transcrip-
tional regulation of cyclin D2 in a variety of cell types
including immune cells and cardiomyocytes [29-31]. Of
these, the Stat5 connection is potentially the most inter-
esting, given the crosstalk between Stat5 and Elf5 in the
prolactin mediated signaling pathway in mammary
glands and hence warrants further investigation [10,32].
The availability of a set of genomic targets of Elf5 in
mammary glands serves as a valuable tool for probing
the molecular function of this transcription factor in
mammary gland biology and has now set the stage for a
rigorous global examination of the Elf5-regulated tran-
scriptome by next generation sequencing.
Methods
Animals
The Elf5-deficient mice utilized in this study have been
described previously [10]. Mice of mixed genetic strain
background (129/Sv × C57BL/6) were used for most
experiments. The genotype of the control wildtype
(WT) animals were either K14-Cre/Elf5
+/+ or Elf5
f/f
whereas Elf5 conditional knockouts were K14-Cre/Elf5
f/
f. Animal procedures were conducted in compliance
with the guidelines of the IACUC Committee of the
State University of New York at Buffalo. For assessing
the pregnancy stages of mammary glands, the mice were
mated and inspected for the presence of vaginal plugs in
t h em o r n i n g s .T h ed a yo ft h ev a g i n a lp l u gw a sc o u n t e d
as day 0.5 d of pregnancy.
Assessment of Elf5 antibody for ChIP
Commercially available anti-ELF5 antibodies were tested
for ChIP by using the HEK293 UAS-TK-Luc cells [33]
according to the method previously described [15]. Two
million cells were cultured in 100 mm plates in DMEM
containing 10% FBS and 1 mg/ml puromycin (Sigma-
Aldrich). When cells reached 30% confluence, 6 μgo f
plasmid DNA pCMV-HA-Gal4DBD or pCMV-HA-
Gal4DBD-ESE2 [13] was transfected using Fugene 6
(Roche Applied Sciences). After 48 hours, transfected
and untransfected control cells were harvested for
downstream application. The crosslinking, immunopre-
cipitation, washing, elution, reverse crosslinking and
proteinase K treatment were performed according to the
manufacturer’s directions described in the Chromatin
Immunoprecipitation (ChIP) Assay Kit (Millipore). Anti-
Gal4 DBD and anti-Elf5 (N-20) antibodies were obtained
from Santa Cruz Biotechnology. The immunoprecipi-
tated DNA was purified with PCR purification kit
(QIAGEN) and eluted in a final volume of 50 μl. PCR
analysis of ChIPed DNA was performed with primers P1
(5′-CACACAGGAAACAGCTATGAC-3′)a n dP 2( 5 ′-
GAATTCGCCAATGACAAGAC-3′). The PCR amplifi-
cation products were analyzed by gel electrophoresis in
a 1.5% agarose gel, visualized with ethidium bromide
staining and pictures were taken.
ChIP assay of mammary glands and cloning of DNA
immunoprecipitated with anti-Elf5 antibodies
Mouse mammary glands (fourth and fifth inguinal) at
pregnancy day 17.5 were excised in aseptic conditions,
weighed and minced in PBS. The tissue fragments
were crosslinked for 5 min at RT in 8 ml of PBS con-
taining 1% formaldehyde (Sigma-Aldrich). The reaction
was stopped by adding glycine (Sigma-Aldrich) to a
final concentration of 125 mM and incubated for an
additional 5 min. The tissue fragments were recovered
by centrifugation for 10 min at 3000 × g, rinsed thrice
with 8 ml of cold PBS, then resuspended in 3 ml of
cold cell lysis buffer (10 mM Tris-HCl, pH 8.0, 10 mM
NaCl, 3 mM MgCl2, 0.5% NP-40) containing 1× of
Protease Arrest (G-Biosciences, St. Louis, MO) and
transferred to a cold Dounce homogenizer. After com-
plete homogenization of the tissue, the nuclei were
pelleted at 12,000 × g for 5 min and resuspended in
200 μl of ChIP lysis buffer (Millipore) per each 100 mg
of tissue, then sonicated 16 times with 15-second
cycles at setting 3 (Branson Sonifier 250) to generate
fragments of 0.5 kb on average. Sonicated samples
were centrifugated at 12,000 ×g for 10 min and the
supernatant was transferred to a new tube. An aliquot
of 190 μl was diluted 10-fold in ChIP dilution buffer
(EZ-ChIP kit, Millipore) and pre-cleared with 75 μlo f
50% protein G-Sepharose beads slurry containing sal-
mon sperm DNA and BSA at 4°C for 30 min. The pre-
cleared chromatin was divided in 600-μla l i q u o t sa n d
immunoprecipitated overnight at 4°C with 10 μgo f
anti-Elf5 (N-20, Santa Cruz Biotechnology) or normal
goat IgG (Santa Cruz Biotechnology) or no antibody as
control. A 6-μl aliquot of pre-cleared chromatin was
saved as input (1%). The immunoprecipitation, wash-
ing, elution, reversing crosslink and proteinase K treat-
ment were performed according to the manufacturer’s
directions described in the EZ-ChIP kit.
After proteinase K treatment, the immunoprecipitated
DNA was purified with the PCR purification kit (QIA-
G E N )a n dD N Aw a se l u t e di naf i n a lv o l u m eo f5 0μl.
After ChIP assay, the Elf5-immunoprecipiated DNA was
polished by blunt ending and amplified by PCR after
addition of terminal linkers as described before [16].
The amplified PCR products were purified using Glu-
tathione Sepharose 4B beads (Amersham Biosciences)
conjugated to GST-Elf5 to enrich for Elf5 binding sites.
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300 μl of elution buffer (1% SDS, 0.1 M NaHCO3)t h e n
phenol extracted, precipitated and resuspended in 25 μl
of TE (10 mM Tris-HCl pH 8.0, 1 mM EDTA). The
recovered DNA was amplified by Jumpstart Taq poly-
merase (Sigma-Aldrich) and the PCR products were
cloned using StrataClone PCR cloning kit (Stratagene).
Bacterial colonies containing the PCR products were
randomly chosen for isolation of plasmid DNA. Plasmid
DNAs were checked for presence of insert by restriction
digestion analysis and sequencing.
RNA extraction and Real time RT-PCR analysis
Mouse mammary glands at pregnancy day 17.5 and lac-
tation day 1 from wild type (WT) and K14-Cre/Elf5
f/f
animals [10] were excised in aseptic conditions. Total
RNA was extracted with TRIzol reagent, according to
the manufacturer’s directions (Invitrogen), then purified
by phenol/chloroform extraction and treated with
TURBO DNAse-free kit (Ambion) to remove genomic
DNA. Total RNA (2 μg) were reverse transcribed using
SuperScript II reverse transcriptase (Invitrogen) accord-
ing to the manufacturer’s directions. Real-time PCR was
performed in a volume of 25 μlc o n t a i n i n g1 ×i QS Y B R
Green Supermix (Bio-Rad Laboratories), 200 nM of
each forward and reverse primers (sequence of gene-
specific primers are listed in Table 2 (Additional File 8),
and 1 μl of cDNA. PCRs were carried out at 95°C for
8.5 min followed by 40 cycles of 95°C for 15 s and 60°C
f o r1m i n .A f t e rc o m p l e t i o no ft h eP C R ,am e l t i n g
curve program (55-95°C with a heating rate of 2°C/min)
was performed to confirm that specific PCR amplifica-
tion products were generated. Relative expression was
determined by the 2
-ΔΔCt method [34] and the house-
keeping gene Gapdh was used to normalize for gene
expression.
Elf5 occupancy by ChIP assay
ChIP assay in whole tissue of mouse mammary glands at
pregnancy day 17.5 was performed as describe above,
with 10 μg of anti-Elf5 (N-20) (Santa Cruz Biotechnol-
ogy) or normal goat IgG (Santa Cruz Biotechnology) or
no antibody as a control. The immunoprecipitated DNA
was analyzed by PCR for Elf5 occupancy and performed
in a volume of 25 μl containing 1× PCR buffer (QIA-
GEN), 1× Q-solution (QIAGEN), 200 μM dNTPs, 2 ng/
ml of each forward and reverse primers (primer
sequences are listed in Table 2), 1.25 U Taq DNA poly-
merase (QIAGEN) and 2 μl of template. The PCRs were
carried out at 95°C for 4 min, followed by 35 cycles of
95°C for 45 s, 56°C or 58°C for 45 s and 72°C for 45 s,
with a final extension step at 72°C for 5 min. The PCR
amplification products were analyzed by gel
electrophoresis.
Protein extract and Western blot analysis
Mouse mammary glands (fourth and fifth inguinal) at
pregnancy day 17.5 and lactation day 1 from wild type
(WT) and K14-Cre/Elf5
f/f animals were excised in asep-
tic conditions and pulverized into powder in a mortar
containing liquid nitrogen, then resuspended in 500 μl
of RIPA buffer (50 mM Tris-HCl pH 8.0, 150 mM
NaCl, 1 mM EDTA, 1% Triton X-100, 1% sodium deox-
ycholate, 0.1% SDS) supplemented with 1× Protease
Arrest (G-Biosciences) and phosphatase inhibitors (1
mM Na3VO4, 10 mM NaF) and extracted for 30 min at
4°C. The samples were centrifuged at 13,000 × g for 30
min and supernatant was collected as extracted protein.
Protein extract were resolved by SDS-PAGE and electro-
phoretically transferred to PVDF (polyvinylidene difluor-
ide) membranes (Bio-Rad). After blocking, the
membranes were probed with primary antibodies fol-
lowed by a second incubation with secondary antibodies
(diluted at 1:20,000 or 1:30,000) conjugated to HRP.
Chemiluminescent detection of HRP-conjugated second-
ary antibodies was accomplished using the LumiGLO
Reserve Chemiluminescent Substrate kit (KPL, Inc). The
primary antibodies were anti-cyclin D2 (Santa Cruz Bio-
technology) diluted at 1:4,000, anti-p27 (Santa Cruz Bio-
technology) diluted at 1:4,000 and anti-Elf5 (Santa Cruz
Biotechnology) diluted at 1:1,000. For loading control,
the membranes were also probed with mouse anti-b
tubulin (Chemicon International) diluted at 1:15,000
and HRP-conjugated antimouse IgG antibody diluted at
1:40,000.
Bioinformatics analysis
Sequenced Elf5-ChIPed DNA clones were analyzed with
the BLAST search of the mouse genome database at
NCBI http://blast.ncbi.nlm.nih.gov/Blast.cgi or
ENSEMBL to identify potential target genes. Gene
located within 100 kb of the ChIPed DNA were consid-
ered as putative Elf5 target genes. Functional categories
of the putative Elf5 target genes were based on gene
ontology described in the Mouse Genome Informatics
http://www.informatics.jax.org/. ChIPed DNA sequences
were analyzed for conservation using the UCSC Genome
Bioinformatics site http://genome.ucsc.edu/.
Plasmid
The minimal promoter region of the mouse cyclin D2
was amplified by PCR from genomic DNA using forward
primer 5′ GTT ATC AGG AGT CAT AGC TTG AGG 3′
and reverse primer 5′ AAG GTG GGC GAG CGG AGC
CTC. The amplified product was cloned into pSC-A-
amp/kan (Strataclone PCR cloning Kit) and then a 645
bp fragment (-545 to +100) transferred into pGL3-basic
vector using HindIII restriction enzyme. The orientation
and lack of any PCR-induced mutation was confirmed by
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where the Elf5-binding site was altered (GAGG > TCTA)
was generated by a two-step PCR procedure described
before and verified by sequencing [35].
Gelshift analysis and purification of GST-proteins
DNA binding reactions were performed as described
previously [36]. Briefly, double-stranded oligonucleotides
were labeled with [
32P]dCTP, using Klenow fragments
to fill in the overhanging 5′ ends. Binding reaction mix-
tures were incubated at room temperature in 1× DNA
binding buffer (20 mM HEPES [pH 7.9], 75 mM KCL,
2.5 mM MgCl2, 1 mM EDTA, 0.5 mM dithiothreitol
and 10% glycerol) containing recombinant protein, 1 μg
of poly(dA-dT) and the labeled probe. Reactions were
then electrophoresed on a 5% nondenaturing polyacryla-
mide gel. Wildtype and mutant GST-Elf5 proteins were
synthesized as described previously [37]. Specific muta-
tions in the ETS-domain of Elf5 were introduced by a
two-step PCR procedure described before [35].
Cell culture, transfections, and reporter assays
MCF-7 cells were maintained in Dulbecco Modified
Eagle Medium supplemented with 10% fetal bovine
serum and antibiotics. Transient transfections were per-
formed in 6-well plates using Fugene6 (Roche) in MCF-
7 cells following the manufacturer’s recommendations.
One microgram each of CMV-HA, CMV-HAElf5,
CMV-HAElf3 and luciferase reporter constructs were
transfected per well along with 0.25 μg of CMVLacZ
plasmid DNA to serve as an internal control for trans-
fection efficiency. Cells were harvested 48 hours post-
transfection and reporter assays were performed as
described previously [35]. Expression of the HA-tagged
Elf5 and Elf3 proteins was detected by western blot ana-
lysis with anti-HA antibodies (Roche, 1:5000 dilution).
Primary mammary epithelial cell (MEC) culture and viral
infection
Isolation and adenoviral transduction of primary mam-
mary epithelial cells were performed as described pre-
viously [7]. Briefly, primary mammary epithelial cells
obtained from Elf5
f/f animals were transduced with Ade-
novirus-Cre (Ad-Cre) in suspension for 45 min before
they were plated on BM (Basement Membrane) matrix
(Matrigel, BD Biosciences). Cells were cultured in Assay
Media [DMEM/F12 medium containing Insulin (5 μg/
ml), Hydrocortisone (1 μg/ml), EGF (10 ng/ml), FBS
(10%), Penicilin/Streptamycin (1×), Gentamycin (50 μg/
ml)].
Immunofluorescence analysis
For immunofluorescence analysis, mammary gland speci-
mens were fixed overnight in neutral buffered formalin
[3.7% formaldehyde buffered to pH 6.8-7.2 with monoba-
sic and dibasic sodium phosphate], dehydrated and
embedded in paraffin. Tissue blocks were sectioned into
5 μm sections which were baked for 30 min at 60°C and
then deparaffinized. Heat-induced antigen retrieval was
performed by microwaving sections in 10 mM sodium
citrate, pH 6.0 for 20 min. After blocking with M.O.M.
kit (Vector Laboratories), sections were incubated with
primary antibodies overnight at 4°C, followed by 45-min
incubation with secondary antibodies. The slides were
mounted with Vectashield (Vector Laboratories), and the
immunofluorescence was viewed under Confocal Micro-
scopy (Leica). The following antibodies and dilutions
were used for immunofluorescence: Ccnd2 (Santa Cruz)
at 1:200, and anti-b-catenin antibody (1:500, Sigma).
Additional material
Additional file 1: Table 1 List of putative Elf5 target genes. Shown
are the genes that are located within 100 Kb of the isolated Elf5-ChIPed
DNAs and the size of the immunoprecipitated DNA fragment that was
sequenced.
Additional file 2: Figure S1 Relative location and the genomic
context of the Elf5 ChIPed segment. Select groups of putative Elf5
target genes chosen for further evaluation are highlighted with their
genomic organization, chromosome number and the position of the
ChIPed DNA fragment.
Additional file 3: Figure S2 Sequence conservation of the upstream
Elf5-ChIPed region. A 10 kb region 5’ of the CCND2 gene was
compared between different species by using the GenomeVISTA
program http://genome.lbl.gov/vista/index.shtml. The segment bound by
Elf5 was highly conserved among several species as indicated by the
box.
Additional file 4: Figure S3 Sequence of the proximal CcnD2
promoter and the upstream region. The core GGAA Elf5-binding
sequence is boxed.
Additional file 5: Figure S4 Purified GST-Elf5 WT and the two DNA-
binding deficient mutants. GST-Elf5 wildtype and GST-Elf5 mutants
were purified using GST-agarose and eluted samples were run on a SDS-
PAGE gel to assess purity and amount of the proteins. The WT1 and WT2
samples represent two independently purified fractions. The mutants,
MT1 and MT2 were K to A substitution at amino acid 216 and R to A
substitution at amino acid 219 respectively, of the mouse Elf5 protein.
Additional file 6: Figure S5 Western blot demonstrating the
expression of HA-Elf5 and HA-Elf3 in transient transfection
experiments. The expression of the HA-epitope tagged Ets proteins was
detected by anti-HA antibodies.
Additional file 7: Figure S6 Increase in Ccnd2 expression in the
absence of Elf5. Elf5
f/f primary mammary epithelial cells (MECs) were
transduced with Ad-Cre in suspension and plated on BM matrix (A).
Western blot analysis of protein lysates from Elf5
f/f MECs transduced with
Ad-Cre resulted in increased Ccnd2 expression. Elf5 is absent in Ad-Cre-
Elf5
f/f cells (B).
Additional file 8: Table 2. Primer sequences used for occupancy
analysis of putative Elf5 target genes, real time RT-PCR and gelshift
experiments.
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